Autologous hematopoietic stem cell transplant with melphalan and thiotepa is safe and feasible in pediatric patients with low normalized glomerular filtration rate
| Autor: | Robin Rosselet, Alfred Grovas, Amanda Termuhlen, Thomas G. Gross, Kathryn J. Klopfenstein |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Melphalan
Vincristine medicine.medical_specialty Urology Renal function ThioTEPA Transplantation Autologous Wilms Tumor chemistry.chemical_compound Neuroblastoma immune system diseases hemic and lymphatic diseases medicine Humans Antineoplastic Agents Alkylating Transplantation business.industry Hematopoietic Stem Cell Transplantation Infant medicine.disease Combined Modality Therapy Nitrogen mustard Kidney Neoplasms Surgery surgical procedures operative Treatment Outcome chemistry Child Preschool Pediatrics Perinatology and Child Health Drug Therapy Combination Female Stem cell business Complication Thiotepa medicine.drug Kidney disease Glomerular Filtration Rate |
| Zdroj: | Pediatric transplantation. 10(7) |
| ISSN: | 1397-3142 |
| Popis: | Normalized glomerular filtration rate (nGFR) < 60 mL/min/ 1.73 m 2 often precludes hematopoietic stem cell transplant (HSCT) in pediatric patients. Three patients with nGFR < 60 mL/min/1.73 m 2 enrolled on an institutional phase I trial of HSCT preparative therapy for advanced and recurrent solid tumors with escalating melphalan, ranging from 135 to 180 mg/m 2 , thiotepa (600 mg/m 2 ), and vincristine (2 mg/m 2 ). An additional patient with low nGFR was treated with the same preparative therapy. None of the patients developed acute renal failure, excess toxicities during HSCT or delayed engraftment. These cases demonstrate that it is feasible and safe to perform HSCT in pediatric patients with low nGFR using melphalan- and thiotepa-based preparative therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|